ArticleSleep & breathing = Schlaf & Atmung2026
Predicting sleep apnea worsening and cardiometabolic risk without treatment.
Article in Sleep & breathing = Schlaf & Atmung, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Sleep quality, disturbance and the prevalence of obstructive sleep apnoea in chronic spontaneous urticaria and associated risk factors.The World Allergy Organization journal · 2026Article
- Validation and implementation of ambulatory obstructive sleep apnea polygraphy screening combined with wearable semi-continuous heart rhythm monitoring in patients with atrial fibrillation: a validation and a pilot study.Frontiers in cardiovascular medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe natural history of untreated obstructive sleep apnea (OSA) and its cardiometabolic consequences are not fully characterized. We aimed to identify predictors of apnea severity progression and incident cardiometabolic comorbidities in untreated patients, comparing continuous and categorical measures of apnea severity.
methodsWe retrospectively studied 538 adults (419 men, 119 women) who underwent two attended overnight polysomnographic evaluations separated by 3.8 ± 2.7 years and declined OSA treatment. Changes in apnea severity were assessed using continuous change in apnea-hypopnea index (ΔAHI) and categorical transitions across standard severity thresholds. Multivariable linear regression was used to identify predictors of ΔAHI, and multivariable logistic regression was used to identify predictors of incident hypertension, diabetes, and cardiovascular disease.
resultsApnea severity and nocturnal hypoxemia worsened significantly over time. In linear regression, worsening ΔAHI was independently associated with higher baseline body mass index (BMI), greater weight gain, more severe baseline hypoxemia, and longer sleep latency, whereas higher baseline AHI was associated with smaller subsequent increases. In contrast, categorical progression to moderate or severe OSA was primarily predicted by baseline BMI. Incident hypertension and diabetes were independently associated with age, baseline BMI, and duration of follow-up, but not with baseline AHI or ΔAHI. Incident cardiovascular disease was independently associated with baseline apnea severity and lower sleep efficiency. Model discrimination ranged from acceptable to good (C-statistics 0.75-0.86).
conclusionIn untreated patients, OSA commonly worsens over time, with progression influenced by obesity, hypoxemia, and sleep quality. Continuous measures of apnea severity capture physiologic progression more sensitively than categorical classifications. Cardiometabolic consequences differ by outcome, with obesity predominating for hypertension and diabetes and apnea severity and sleep fragmentation more closely linked to cardiovascular disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.